Somija - somu - Fimea (Suomen lääkevirasto)

stada arzneimittel ag - darunavir - tabletti, kalvopäällysteinen - 800 mg - darunaviiri

Somija - somu - Fimea (Suomen lääkevirasto)

sandoz a/s - darunavir - tabletti, kalvopäällysteinen - 800 mg - darunaviiri

Somija - somu - Fimea (Suomen lääkevirasto)

sandoz a/s - darunavir - tabletti, kalvopäällysteinen - 600 mg - darunaviiri

Somija - somu - Fimea (Suomen lääkevirasto)

stada arzneimittel ag - darunavir - tabletti, kalvopäällysteinen - 600 mg - darunaviiri

Somija - somu - Fimea (Suomen lääkevirasto)

medical valley invest ab - darunavir propylene glycolate - tabletti, kalvopäällysteinen - 600 mg - darunaviiri

Eiropas Savienība - somu - EMA (European Medicines Agency)

janssen-cilag international nv - darunaviiria - hiv-infektiot - antiviraalit systeemiseen käyttöön - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Eiropas Savienība - somu - EMA (European Medicines Agency)

janssen-cilag international nv - darunaviiri, cobicistat, emtrisitabiini, tenofoviiri alafenamide - hiv-infektiot - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza on tarkoitettu hoito immuunikatoviruksen virus tyyppi 1 (hiv‑1) tartunnan aikuisille ja nuorille (alle 12-vuotiaat ja vanhemmat kanssa kehon paino on vähintään 40 kg). genotypic testing should guide the use of symtuza.

Eiropas Savienība - somu - EMA (European Medicines Agency)

janssen-cilag international n.v. - darunaviiri, cobicistat - hiv-infektiot - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - rezolsta, tarkoitettu käytettäväksi yhdessä muiden antiretroviruslääkkeiden lääkkeiden hoitoon 1 tyypinvasta (hiv 1) infektio aikuisilla 18 vuoden ikäinen tai vanhempi. genotyyppinen testaus olisi oppaan käytön rezolsta.

Somija - somu - Fimea (Suomen lääkevirasto)

tabletti, kalvopäällysteinen - j05ae10 darunaviiri [näytä works saman ryhmän lääkevalmisteet] - resepti - 800 mg

Eiropas Savienība - somu - EMA (European Medicines Agency)

gilead sciences ireland uc - cobicistat - hiv-infektiot - antiviraalit systeemiseen käyttöön - tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (hiv-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co‑administered with atazanavir orweighing at least 40 kg co‑administered with darunavir.